White Papers

Provided By:

Health Advances

July 25, 2018

By Mike Davitian, Haley Fitzpatrick, Grace Perkins, Tara Breton, Remy Denzler, and Dean Giovanniello In business, we all know it is important to make a good first impression, but in pharma, that may be understating it: an effective commercial launch may swing cumulative reve … Read More »

Provided By:

W2O Group

July 24, 2018

Who is an Influencer? Who is a Key Opinion Leader (KOL)? These questions used to be easily answered with clear data and research tools. While additional dimensions always existed, they were hard to discern. And now, social and digital activity have expanded the definition of … Read More »

Provided By:

S3 Connected Health

June 21, 2018

This installment of our whitepaper series discusses what it means to engage patients effectively, and why digital behavioral change interventions (DBCIs) need to ensure a strong patient engagement strategy is at its core. Request the full Exclusive whitepaper which includes … Read More »

Provided By:


June 4, 2018

As the complexity of precision oncology trials increase, drug developers are facing the paradox of patient scarcity in the presence of data abundance. Using the right technologies can help to solve this paradox. Read our white paper to learn more.  

Provided By:


May 25, 2018

Disruptive Innovation in the Life Science Industry At a panel session hosted by ICON early in 2018, senior executives from leading pharma companies shared their views on ‘Disruptive Innovation’. The session was chaired by Nuala Murphy (President, Clinical Research Services, … Read More »

Provided By:

TrialCard Incorporated

April 25, 2018

In a reported effort to reduce health plan spend for specialty drugs, pharmacy benefit managers have begun promoting “co-pay accumulator” programs to health plan sponsors. The effect of these programs is often to shift much of the cost burden for expensive specialty drugs to … Read More »

Provided By:

WIRB Copernicus Group

April 1, 2018

Research sites are critically important to the development and testing of new therapies. They help bring new treatments to patients—and provide the reliable data that stops the development of unsuccessful projects. While active, organized sites are essential to support the c … Read More »

Provided By:

Quorum Review IRB

March 22, 2018

Recruitment materials are the first introduction to a study for potential participants, and post-consent materials can influence decisions about continued participation. It is important to adhere to the principles of subject protection—that is, allowing subjects to make info … Read More »

Provided By:


February 27, 2018

BulletinHealthcare ran an analysis of their audience of verified physicians, and found that they can reach 40,000 physicians who work in teaching hospitals that do not allow pharma reps access. Download the whitepaper to see where.

Provided By:


January 2, 2018

TrialCard Addresses AB 265 On October 9, 2017, California Governor Jerry Brown signed AB 265 into law. This landmark piece of legislation modified the California Health and Safety Code to prohibit the “offering” of any discount, product voucher, or other out-of-pocket cost r … Read More »

Provided By:


January 1, 2018

As clinical trials become more complex and increasingly global, the problem of over-distributing expedited safety reports to investigative sites has reached the point that demands a solution. The excessive volume of safety reports can cause investigators to miss important re … Read More »

Provided By:

Atlantis Healthcare

December 18, 2017

The latest White Paper from the health psychology experts at Atlantis Healthcare examines how collaborative communication between healthcare professionals and their patients (the ‘therapeutic alliance’) can lead to improved patient outcomes. The paper explores the role playe … Read More »

Provided By:

ACM Global Laboratories

November 16, 2017

The emergence of digital pathology presents an opportunity for central laboratories to support highly targeted therapeutics and precision medicine even further, offering many advantages to both diagnostic and clinical trials testing. This paper explains the noteworthy progre … Read More »

Provided By:


October 25, 2017

The term customer experience (CX) might be relatively new in pharma but the reality is as old as the industry itself. Every time a company interacts with a customer, it is delivering some sort of customer experience. In our increasingly multi-stakeholder and multichannel wor … Read More »

Provided By:


October 18, 2017

Ensuring a patient-first strategy drives real results in commercial pharma Does patient centricity work? Actually, yes. There are increasing volumes of evidence that demonstrate that when you focus on the difference you make to patients, your commercial performance will impr … Read More »

Provided By:


October 17, 2017

How Properly Timed, Targeted Engagement Tactics can Increase Adherence and Brand Revenue Co-pay savings programs are powerful brand marketing tools; not just because of their ability to introduce new patients to therapy, but also due to the wealth of patient behavior data th … Read More »

Provided By:


October 13, 2017

Why a Qualitative Lead Generation Approach Is a Must-Have Component of Any Orphan Drug Sales Strategy Finding patients with rare diseases requires both a quantitative and a qualitative approach. By taking analytics one step further and using a hands-on approach, TrialCard’s … Read More »

Provided By:


October 6, 2017

Cell and gene therapies coming to market hold the potential to redefine every commercialization paradigm – from how products come to market, to how the therapies are transported, to how patients and providers are supported. What can therapy innovators do to ensure commercial … Read More »

Provided By:

Zephyr Health

September 26, 2017

New report: How one company increased revenue by 33% leveraging customer network relationships Breaking the ice can be hard. Establishing new relationships, including potential customer relationships, is easier when you get an introduction from someone in your shared network … Read More »

Provided By:

Cello Health

September 7, 2017

The rare disease landscape is changing: with assets being granted expedited review, launch is no longer a fixed point in time, and research and development (R&D), medical affairs, and commercial teams need to collaborate early in the process to reach critical consensus o … Read More »

Provided By:


August 31, 2017

Rapid-cycle analytic technologies represent an important advance in the pursuit of improved evidence generation practices – but this is only the first step. Learn how RWE technology is evolving through standardization, efficiency, and democratization of data.

Provided By:

Medidata Solutions

August 1, 2017

Globalization of clinical trials, tightening regulatory requirements, a more competitive and collaborative commercial environment, and an increasingly mobile workforce requires life-sciences companies to standardize and improve regulated content management processes to ensur … Read More »